Drug Profile
Research programme: thrombopoietin antibody mimetic - Alexion AstraZeneca Rare Disease
Alternative Names: Fab59Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Class
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 01 Jun 2007 Preclinical trials in Thrombocytopenia in USA (Parenteral)